These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 35774848)

  • 1. Identification of CXCR4 Upregulation in Diffuse Large B-Cell Lymphoma Associated with Prognostic Significance and Clinicopathological Characteristics.
    Zhang YA; Yang X; Yao J; Ren Y; Liu P
    Dis Markers; 2022; 2022():3276925. PubMed ID: 35774848
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dysregulated CXCR4 expression promotes lymphoma cell survival and independently predicts disease progression in germinal center B-cell-like diffuse large B-cell lymphoma.
    Chen J; Xu-Monette ZY; Deng L; Shen Q; Manyam GC; Martinez-Lopez A; Zhang L; Montes-Moreno S; Visco C; Tzankov A; Yin L; Dybkaer K; Chiu A; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Choi WW; van Krieken JH; Huh J; Ponzoni M; Ferreri AJ; Zhao X; Møller MB; Farnen JP; Winter JN; Piris MA; Pham L; Young KH
    Oncotarget; 2015 Mar; 6(8):5597-614. PubMed ID: 25704881
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical significance of chemokine receptor CXCR4 and mammalian target of rapamycin (mTOR) expression in patients with diffuse large B-cell lymphoma.
    Xu ZZ; Shen JK; Zhao SQ; Li JM
    Leuk Lymphoma; 2018 Jun; 59(6):1451-1460. PubMed ID: 28952842
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CXCR4 and CCR7 Expression in Primary Nodal Diffuse Large B-Cell Lymphoma-A Clinical and Immunohistochemical Study.
    Du H; Zhang L; Li G; Liu W; Tang W; Zhang H; Luan J; Gao L; Wang X
    Am J Med Sci; 2019 Apr; 357(4):302-310. PubMed ID: 30904045
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HIF-1α mediates CXCR4 transcription to activate the AKT/mTOR signaling pathway and augment the viability and migration of activated B cell-like diffuse large B-cell lymphoma cells.
    Jin Z; Xiang R; Dai J; Wang Y; Xu Z
    Mol Carcinog; 2023 May; 62(5):676-684. PubMed ID: 36789975
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Significance of
    Ting CY; Chang KM; Kuan JW; Sathar J; Chew LP; Wong OJ; Yusuf Y; Wong L; Samsudin AT; Pana MNBM; Lee SK; Gopal NSR; Puri R; Ong TC; Bahari SK; Goh AS; Teoh CS
    Int J Med Sci; 2019; 16(4):556-566. PubMed ID: 31171907
    [No Abstract]   [Full Text] [Related]  

  • 7. ASB2 is a direct target of FLI1 that sustains NF-κB pathway activation in germinal center-derived diffuse large B-cell lymphoma.
    Sartori G; Napoli S; Cascione L; Chung EYL; Priebe V; Arribas AJ; Mensah AA; Dall'Angelo M; Falzarano C; Barnabei L; Forcato M; Rinaldi A; Bicciato S; Thome M; Bertoni F
    J Exp Clin Cancer Res; 2021 Nov; 40(1):357. PubMed ID: 34763718
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery and validation of immune-associated long non-coding RNA biomarkers associated with clinically molecular subtype and prognosis in diffuse large B cell lymphoma.
    Zhou M; Zhao H; Xu W; Bao S; Cheng L; Sun J
    Mol Cancer; 2017 Jan; 16(1):16. PubMed ID: 28103885
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CCL8 as a promising prognostic factor in diffuse large B-cell lymphoma
    Lou X; Zhao K; Xu J; Shuai L; Niu H; Cao Z; Wang J; Zhang Y
    Front Immunol; 2022; 13():950213. PubMed ID: 36072582
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identifying
    Xiang X; Gao LM; Zhang Y; Zhu Q; Zhao S; Liu W; Ye Y; Tang Y; Zhang W
    PeerJ; 2023; 11():e16618. PubMed ID: 38099311
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CXCR4 upregulation is an indicator of sensitivity to B-cell receptor/PI3K blockade and a potential resistance mechanism in B-cell receptor-dependent diffuse large B-cell lymphomas.
    Chen L; Ouyang J; Wienand K; Bojarczuk K; Hao Y; Chapuy B; Neuberg D; Juszczynski P; Lawton LN; Rodig SJ; Monti S; Shipp MA
    Haematologica; 2020 May; 105(5):1361-1368. PubMed ID: 31471373
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program.
    Hu S; Xu-Monette ZY; Tzankov A; Green T; Wu L; Balasubramanyam A; Liu WM; Visco C; Li Y; Miranda RN; Montes-Moreno S; Dybkaer K; Chiu A; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Choi WW; Zhao X; van Krieken JH; Huang Q; Huh J; Ai W; Ponzoni M; Ferreri AJ; Zhou F; Slack GW; Gascoyne RD; Tu M; Variakojis D; Chen W; Go RS; Piris MA; Møller MB; Medeiros LJ; Young KH
    Blood; 2013 May; 121(20):4021-31; quiz 4250. PubMed ID: 23449635
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Specific Cytotoxic Effect of an Auristatin Nanoconjugate Towards CXCR4
    Falgàs A; Pallarès V; Unzueta U; Núñez Y; Sierra J; Gallardo A; Alba-Castellón L; Mangues MA; Álamo P; Villaverde A; Vázquez E; Mangues R; Casanova I
    Int J Nanomedicine; 2021; 16():1869-1888. PubMed ID: 33716502
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinicopathological characteristics and genomic profile of primary sinonasal tract diffuse large B cell lymphoma (DLBCL) reveals gain at 1q31 and RGS1 encoding protein; high RGS1 immunohistochemical expression associates with poor overall survival in DLBCL not otherwise specified (NOS).
    Carreras J; Kikuti YY; Beà S; Miyaoka M; Hiraiwa S; Ikoma H; Nagao R; Tomita S; Martin-Garcia D; Salaverria I; Sato A; Ichiki A; Roncador G; Garcia JF; Ando K; Campo E; Nakamura N
    Histopathology; 2017 Mar; 70(4):595-621. PubMed ID: 27775850
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PIM kinases are progression markers and emerging therapeutic targets in diffuse large B-cell lymphoma.
    Brault L; Menter T; Obermann EC; Knapp S; Thommen S; Schwaller J; Tzankov A
    Br J Cancer; 2012 Jul; 107(3):491-500. PubMed ID: 22722314
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MicroRNA-21 plays an oncogenic role by targeting FOXO1 and activating the PI3K/AKT pathway in diffuse large B-cell lymphoma.
    Go H; Jang JY; Kim PJ; Kim YG; Nam SJ; Paik JH; Kim TM; Heo DS; Kim CW; Jeon YK
    Oncotarget; 2015 Jun; 6(17):15035-49. PubMed ID: 25909227
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FOXP2-positive diffuse large B-cell lymphomas exhibit a poor response to R-CHOP therapy and distinct biological signatures.
    Wong KK; Gascoyne DM; Soilleux EJ; Lyne L; Spearman H; Roncador G; Pedersen LM; Møller MB; Green TM; Banham AH
    Oncotarget; 2016 Aug; 7(33):52940-52956. PubMed ID: 27224915
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinicopathologic implication of microRNA-197 in diffuse large B cell lymphoma.
    Yang JM; Jang JY; Jeon YK; Paik JH
    J Transl Med; 2018 Jun; 16(1):162. PubMed ID: 29890998
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comprehensive analysis of the prognostic implication and immune infiltration of CISD2 in diffuse large B-cell lymphoma.
    Zhang C; Lin Q; Li C; Qiu Y; Chen J; Zhu X
    Front Immunol; 2023; 14():1277695. PubMed ID: 38155967
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CXCR4 expression enhances diffuse large B cell lymphoma dissemination and decreases patient survival.
    Moreno MJ; Bosch R; Dieguez-Gonzalez R; Novelli S; Mozos A; Gallardo A; Pavón MÁ; Céspedes MV; Grañena A; Alcoceba M; Blanco O; Gonzalez-Díaz M; Sierra J; Mangues R; Casanova I
    J Pathol; 2015 Feb; 235(3):445-55. PubMed ID: 25231113
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.